No, I think its less:
Former Zantac makers GSK, Pfizer, Sanofi and Boehringer Ingelheim are facing about 4,000 claims in California state court and about 2,000 in various other state courts around the country.
The bulk of the cases against GSK are in Delaware, where the British drugmaker faces more than 70,000 lawsuits. |
Only another 153000 to go-that's the problem. |
2 more Zantac settlements. |
 GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIXSource: Business WireTrial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate administrationCo-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety profilesThese data advance the science of co-administration of recommended adult vaccinesGSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), both AS01-adjuvanted vaccines (NCT05966090).1,2 The data were presented as a late-breaking abstract at the European Geriatric Medicine Society (EuGMS) Congress in Valencia, Spain (September 18-20th, 2024).2 SHINGRIX is approved for the prevention of shingles (herpes zoster) in adults aged 50 years and older. AREXVY is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older, as well as individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV. |
Short term it will head up and down with the market. Longer term I expect them to significantly outperform the market |
Same old GSK! |
Filtered for telling the truth! |
Spoole filtered for deramping... |
Heading back to the 1500s |
Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma accepted for regulatory review in Japan
· Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials
· If approved, Blenrep plus BorDex or PomDex could redefine relapsed/refractory multiple myeloma treatment landscape
· More than 7,200 new cases of multiple myeloma are diagnosed in Japan each year |
You must be confident of a few more quid on this if you're in at this price. I am too.. eventually! |
IN @ 1631.39 ..... ;o) |
Blenrep (belantamab mafodotin) in combination receives Breakthrough Therapy Designation in China for treatment of relapsed/refractory multiple myeloma.
Granted based on results from phase III head-to-head DREAMM-7 trial
Designation expedites development of investigational drugs with potential for substantial improvement over available therapies
Novel therapies needed in multiple myeloma as patients typically relapse or stop responding to initial treatments |
GSK announced positive results from a phase two trial of its mRNA-based seasonal flu vaccine on Thursday, showing improved immune responses against A and B strains in both younger and older adults compared to the standard of care. The FTSE 100 pharmaceuticals giant said the vaccine demonstrated strong antibody levels and an acceptable safety profile across all tested formulations. Based on the findings, GSK said it now planned to advance the vaccine program to phase three clinical trials. |
Issued: 12 September 2024, London UK
GSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme
· A vaccine candidate formulation demonstrated positive A and B strain immune responses relative to standard of care in both younger and older adults
· mRNA platform elicits strong overall antibody titres with an acceptable safety profile
· Data support progression to phase III clinical trials
GSK plc (LSE/NYSE: GSK) today announced positive headline results of a phase II trial (NCT06431607) for its mRNA seasonal influenza vaccine programme. The trial studied a range of mRNA formulations in older and younger adults to evaluate vaccine candidates that could improve immune responses against influenza A and B strains, compared to the current standard of care.
In both younger and older adults, pre-defined success criteria were met. Interim data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested.
These results build on the previous phase II trial and confirm the mRNA platform elicits strong overall antibody titres with an acceptable safety profile. With these results, the GSK mRNA seasonal influenza vaccine programme will progress into late-stage clinical development.
GSK's Chief Scientific Officer, Tony Wood said: "This marks a significant advancement in our mRNA programme and these data support moving into late-stage development. Ultimately, our goal is to develop a new best-in-class vaccine to bring greater protection to people through the influenza season."
GSK recently signed a new licensing agreement with CureVac to assume full control of developing and manufacturing influenza and COVID-19 candidate vaccines. GSK continues to develop and optimise its mRNA capabilities through investments and partnerships, including in AI/ML-based sequence optimisation, nanoparticle design and manufacturing.
About study NCT06431607
The phase II study assesses the reactogenicity, safety, and immunogenicity of different dose levels of a modified, multivalent vaccine candidate, encoding antigens matched to all three WHO-recommended influenza strains. The study includes 250 healthy younger adults aged 18 to 64 and 250 healthy older adults aged 65 to 85. In each age group, different dose levels were tested in comparison to an age-appropriate, licensed comparator vaccine.
|
Issued: 11 September 2024, London UK
Statement: Zantac (ranitidine) litigation - Dixon case
GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Mr. Isaac Dixon, resolving the prostate cancer case filed in Illinois State Court. GSK does not admit any liability in this settlement. The case will now be dismissed.
Since 2019, following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.
GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. |
GlaxoSmithKline has announced promising results from their SWIFT-1 and SWIFT-2 phase III clinical trials of depemokimab, showing a 54% reduction in severe asthma exacerbations over a year. The biologic, intended for severe asthma patients with type 2 inflammation, is administered once every six months and has also shown to significantly reduce hospitalizations. These findings, also published in the New England Journal of Medicine, are set to inform future regulatory filings as depemokimab is not yet approved for use. |
GSK respiratory medicine Nucala's positive late-stage trial in adults with chronic obstructive pulmonary disease improves the company's long-term growth perspective, Shore Capital analyst Sean Conroy says in a note. A regulatory approval of the drug for patients with COPD could generate 0.5 billion-1 billion pounds in annual sales, offsetting part of an expected overall sales decline from 2027 as patents expire. In addition, the British pharma giant will next week present late-stage trial information regarding its additional respiratory medicine depemokimab for severe uncontrolled asthma, for which the company anticipates a potential of more than 3 billion pounds in peak year sales. |
Hi DaviusDon't suppose you (or others) have any idea when the Delaware Supreme Court might have their decision scheduled for? Just looking for timelines to guide buy/sell/trade.Thanks |
European Commission approves expanded age indication for GSK's Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
· An estimated 20 million adults aged 50-59 in 30 European countries have a medical condition that increases their risk for RSV disease.
· Authorisation helps protect this population for the first time ahead of this RSV season
· This follows approval in US, with other countries anticipated, including Japan later this year. |
#Abdullla, just the 14:30 US market opening drag, see where we close at, the trend is very much intact from September 2022, 1800 the next barrier to clear.. :o) |
Sudden share price drop!where is the bad news ? |
In London, GSK shares rose 2.1%. The London-based pharmaceutical company welcomed the Delaware Supreme Court's decision to review the Delaware Superior Court's decision allowing the introduction of plaintiffs' expert evidence at trial regarding heartburn drug Zantac, which had been pulled off the market in 2020 at the request of the FDA.
The Delaware Supreme Court will review the Delaware Superior's Court decision according to the Daubert standard, which in the US provides criteria for evaluating whether expert testimony is admissible.
Zantac had been pulled off the market after low levels of a "probable carcinogen" were found in samples. The carcinogen, known as NDMA, is not harmful in very small amounts. However, tests showed that there were excessive quantities of NDMA in ranitidine, otherwise known as Zantac. Multiple litigations have followed.
GSK said Wednesday: "The scientific consensus remains that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. Since 2019, there are 16 epidemiological studies looking at human data regarding the use of ranitidine, including outcomes for more than 1 million patients using ranitidine, supporting this consensus." |
REDUCED 996 @ 1642.1p ..... ;0) |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
